Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HRTX with free AI briefings, catalyst countdowns, and dilution alerts.

HRTX · HERON THERAPEUTICS, INC. /DE/

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$23.4M Cash on Hand
46.8mo Cash Runway
Follow HRTX by email Get an email when HRTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HRTX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bupivacaine And Meloxicam
FDA approved May 2021 · Zynrelef Kit
Post Operative Pain, Acute Phase 4 · NCT05863221 Unknown
Granisetron
FDA approved Aug 2016 · Sustol (discontinued)
Chemotherapy-Induced Nausea and Vomiting (CINV) Phase 4 · NCT05434663 Active not recruiting
Aprepitant
FDA approved Nov 2017 · Cinvanti
PONV Phase 4 · NCT07639723 Not yet recruiting
Tilarginine Postoperative Pain Phase 4 · NCT06109428 Completed
Liposomal Bupivacaine Analgesia Phase 4 · NCT04102267 Completed
Bupivacaine Hydrochloride Analgesia Phase 4 · NCT05109312 Active not recruiting
Bupivacaine HCl without epinephrine via… Analgesia Phase 4 · NCT04102267 Completed
APF530 Chemotherapy-induced Nausea and Vomiting Phase 3 · NCT02106494 Completed
Fosaprepitant Chemotherapy-induced Nausea and Vomiting Phase 3 · NCT02106494 Completed
Bupivacaine HCl without epinephrine Postoperative Pain Phase 2 · NCT03011333 Completed
Bupivacaine HCI without epinephrine Post-Operative Pain Phase 2 · NCT04911062 Completed
Ropivacaine Postoperative Pain Phase 2 · NCT03015532 Completed
Bupivicaine HCl Postoperative Pain Phase 2 · NCT02689258 Completed
Aprepitant injectable emulsion COVID-19 Phase 2 · NCT04470622 Terminated
Ketorolac Postoperative Pain Phase 2 · NCT03695367 Completed
F18 FBPA Injection Solid Tumor Phase 1/2 · NCT07691775 Recruiting

Also used in these trials (approved or third-party drugs, not HRTX's own candidates): Acetaminophen, Ondansetron, Ibuprofen, Dexamethasone, Palonosetron Hydrochloride, Celecoxib, Bupivacaine Hci.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HRTX holds $23.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.5M/quarter from operations, an estimated runway of 46.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HRTX files for a raise →

👥 Who Owns HRTX

Insiders 5.7% Institutions (203 holders) 68.1% Public and other holders 26.2%
HolderTypeShares% of sharesAs of
Rubric Capital Management LP Institution (13G, 5%+) 30,046,828 15.79% 2025-10-15
Clearline Capital LP Institution (13G, 5%+) 12,235,239 6.43% 2025-12-31
Adam Morgan
Director
Insider 8,877,027 4.67% 2026-01-30
Craig A Collard
Chief Executive Officer, Director · +1.91M options
Insider 931,086 0.49% 2026-10-30
Ira Duarte
EVP, Chief Financial Officer · +538,372 options
Insider 302,724 0.16% 2026-10-30
William P Forbes
EVP, Chief Development Officer · +481,878 options
Insider 260,734 0.14% 2026-10-30
Mark Earl Hensley
Chief Operating Officer · +689,129 options
Insider 201,683 0.11% 2026-11-06
Craig A Johnson
Director
Insider 53,960 0.03% 2026-01-30
Thomas Cusack
Director · +227,272 options
Insider 53,960 0.03% 2026-01-30
Waage Christian
Director
Insider 53,960 0.03% 2026-01-30
Michael Kaseta
Director
Insider 53,960 0.03% 2026-01-30
Sharmila Dissanaike
Director
Insider 53,960 0.03% 2026-01-30

Share count 190,273,587 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HRTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HRTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.